Japan’s Takeda Sees Largest Earnings Gain In Six-Plus Years
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical registered its biggest stock market gain in six years after an analyst noted the Japanese firm was experiencing steady earnings. The Nikko Citigroup analyst also noted, however, that Takeda still does not have a successor for its Actos (pioglitazone hydrochloride) diabetes drug, whose patent is set to expire in 2011. He said Takeda is looking to its SYR-322 (alogliptin) type 2 diabetes drug and a joint-venture stomach ulcer drug to counter the expected decline in Actos sales, and has ample cash for mergers and acquisitions. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.